Know Cancer

or
forgot password

    • cancer clinical trials in kingston, PA

    • A Study Of Oral PD-0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Neoplasms, Lymphoma, Non-Hodgkin
    Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Chronic Myeloid Leukemia
    Study Evaluating CMC-544 Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Lymphoma, B-Cell
    Adj TC + Herceptin Early Stage Breast Cancer
    Medical Oncology Associates
    Kingston, Pennsylvania 18704
    Breast Cancer
    TAC Versus TC for Adjuvant Breast Cancer
    Medical Oncology Associates
    Kingston, Pennsylvania 18704
    Breast Cancer
    Docetaxel+Oxali+/-Cetux Met Gastric/GEJ
    Medical Oncology Associates
    Kingston, Pennsylvania 18704
    Metastatic Gastric or GEJ Cancer
    Phase II Sunitinib Prog Met AIPC
    Medical Oncology Associates
    Kingston, Pennsylvania 18704
    Metastatic Prostate Cancer
    Prospective Observational Epidemiologic Study of Maraviroc's Safety
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Human Immunodeficiency Virus
    Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Kidney Neoplasms
    Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Breast Cancer, Advanced Malignant Solid Tumors
    Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Advanced Breast Cancer, Breast Cancer
    Gemzar, Cisp, Sunitinib Urothelial Ca
    Medical Oncology Associates of Wyoming Valley, PC
    Kingston, Pennsylvania 18704
    Urothelial Cancer
    Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Solid Tumors
    Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Lymphoma
    Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Breast Cancer
    Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Kidney Neoplasms
    A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
    Medical Oncology Associates of Wyoming Valley
    Kingston, Pennsylvania 18704
    Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
    Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Lymphoma, B-Cell
    Ixabepilone + Carboplatin Metastatic Breast Cancer
    Medical Oncology Associates of Wyoming Valley, PC
    Kingston, Pennsylvania 18704
    Metastatic Breast Cancer
    Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
    US Oncology - Medical Oncology Associates (Nahar)
    Kingston, Pennsylvania 18704
    Chronic Lymphocytic Leukemia
    Connect® MM- The Multiple Myeloma Disease Registry
    US Oncology - Medical Oncology Associates (Nahar)
    Kingston, Pennsylvania 18704
    Multiple Myeloma
    Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
    Medical Oncology Associates of Wyoming Valley, PC
    Kingston, Pennsylvania 18704
    Chronic Myeloid Leukemia
    Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
    Medical Oncology Associates of Wyoming Valley, P.C.
    Kingston, Pennsylvania 18704-5527
    Breast Cancer
    ARCHER 1009 : A Study Of PF-00299804 (Dacomitinib) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Non-Small Cell Lung Cancer (NSCLC)
    A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Endometrial Neoplasms
    The BEACON Study (Breast Cancer Outcomes With NKTR-102)
    Medical Oncology Associates of Wyoming Valley, PC
    Kingston, Pennsylvania 18704
    Locally Recurrent Breast Cancer, Metastatic Breast Cancer
    Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)
    Medical Oncology Associates of Wyoming Valley, PC
    Kingston, Pennsylvania 18704
    Extensive-Stage Small Cell Lung Cancer
    Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
    Medical Oncology Associates of Wyoming Valley, P.C.
    Kingston, Pennsylvania 18704-5527
    Pancreatic Cancer
    For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Neoplasm Metastasis, Colorectal Neoplasms
    Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Sarcoma
    Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Non-Hodgkin Lymphoma, Hodgkin Disease, Thrombocytopenia
    A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Lung Neoplasms
    A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes
    Medical Oncology Associates
    Kingston, Pennsylvania 18704
    Myelodysplastic Syndromes
    Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
    Medical Oncology Associates of Wyoming Valley, PC
    Kingston, Pennsylvania 18704
    Non-small Cell Lung Cancer
    A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Breast Neoplasms
    Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Kidney Neoplasms
    Treatment With SU11248 in Patients With Neuroendocrine Tumors
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Neuroendocrine Tumors
    Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Carcinoma, Renal Cell, Kidney Neoplasms
    Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Lymphoma, B-Cell
    A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Lung Neoplasms
    A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Gastrointestinal Stromal Tumor
    Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Kidney Neoplasms
    A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Carcinoma, Renal Cell
    SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Carcinoma, Renal Cell
    A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients
    Medical Oncology Associates of Wymoning Valley, PC
    Kingston, Pennsylvania 18704
    Non-Small Cell Lung Cancer
    Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Carcinoma, Non-Small-Cell Lung
    Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Thyroid Neoplasms
    Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Melanoma, Skin Neoplasms
    Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Colorectal Neoplasms
    Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Colorectal Neoplasms, Liver Neoplasms
    Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Adenocarcinoma, Neoplasms
    A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Non-small Cell Lung Cancer
    Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Carcinoma, Renal Cell
    Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Lymphoma
    Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Carcinoma, Renal Cell
    Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Adenocarcinoma
    Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Colorectal Adenoma
    Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Osteoporosis
    A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer
    Pfizer Investigational Site
    Kingston, Pennsylvania 18704-5535
    Neoplasms, Lymphoma, Non-Hodgkin